Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries. [PDF]
BMC Health Serv Res, 2022 Yoo HK +7 more
europepmc +1 more source
Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with Ankylosing Spondylitis. [PDF]
J Clin Med, 2021 Lee SS +6 more
europepmc +1 more source
CT-P13: a safe and effective treatment for IBD [PDF]
Nature Reviews Gastroenterology & Hepatology, 2016 openaire +1 more source
Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. [PDF]
J Gastroenterol Hepatol, 2021 Sagami S +5 more
europepmc +1 more source
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. [PDF]
, 2015 Cantini F +11 more
core +1 more source
Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST). [PDF]
Rheumatol Adv Pract, 2021 Taylor PC +8 more
europepmc +1 more source
Antibodies to Infliximab in Patients Treated with Either the Reference Biologic or the Biosimilar CT-P13 Show Identical Reactivity Towards Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease [PDF]
Gastroenterology, 2017 Fiorino G +11 more
openaire +3 more sources
Exploring the Reasons Behind the Substantial Discontinuation Rate Among Patients Taking CT-P13 in a Large Tertiary Hospital in Western Switzerland: A Retrospective Cohort Study Using Routinely Collected Medical Data. [PDF]
Drugs Real World Outcomes, 2022 Krstic M +3 more
europepmc +1 more source
Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration’ by Marshall et al. [PDF]
, 2016 Emery, P +3 more
core +1 more source